 MONT-SAINT-GUIBERT, Belgium, May 06, 2020 GLOBE NEWSWIRE -- Celyad Euronext Brussels and Paris, and Nasdaq: CYAD, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that Dr. Maria Koehler and Mr. Dominic Piscitelli have been appointed as independent members to its Board of Directors, effective as of March 24 and May 6, respectively. We are delighted to announce the appointment of Dr. Maria Koehler and Mr. Dominic Piscitelli to our Board of Directors given the tremendous industry experience and wealth of knowledge both will offer Celyad as we continue to build an oncology-focused organization rich with expertise, said Filippo Petti, Chief Executive Officer of Celyad. 